In summary, we demonstrated that localized knockdown of Ripk1 mRNA and Nsf mRNA mediated by CRISPR-CasRx in the striatum and S1BF leads to a reduction in stroke size and an improvement in neurological deficits in a mouse model of tMCAO. Here, RIPK1 is linked to stroke disorder.